William P. Esler
Research Subjects
William P. Esler has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
Jeffrey A. Pfefferkorn
Internal Medicine Research Unit, Pfizer Inc, Cambridge, USA
6 shared publicationsTrenton T. Ross
Internal Medicine Research Unit, Pfizer Inc, Cambridge, USA
5 shared publicationsArthur Bergman
Early Clinical Development, Pfizer Inc, Cambridge, USA
4 shared publicationsCollin Crowley
Internal Medicine Research Unit, Pfizer Inc, Cambridge, USA
4 shared publications- Aditi R. Saxena
Pfizer Worldwide Research and Development Cambridge Massachusetts USA
3 shared publications - Kendra K. Bence
Internal Medicine Research Unit, Pfizer Worldwide Research, Development, and Medical, Cambridge, Massachusetts, USA
3 shared publications
Latest Publications
- 7 October 2026
- Published by Springer Nature in Nature Metabolism
- Vol. 8 (10) , 2165-2177
Metabolic benefits of ketohexokinase inhibition in individuals with MASLD: a randomized placebo-controlled crossover trial
- 7 October 2026
- Published by Springer Nature in Nature Metabolism
- Vol. 8 (10) , 2165-2177
Metabolic benefits of ketohexokinase inhibition in individuals with MASLD: a randomized placebo-controlled crossover trial
- Open Access
- 11 February 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (6)
Safety and efficacy of pharmacological inhibition of ketohexokinase in hereditary fructose intolerance
- 11 February 2025
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 135 (6)
Open AccessSafety and efficacy of pharmacological inhibition of ketohexokinase in hereditary fructose intolerance
- Open Access
- 16 February 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (2) , e13687
Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants
Co‐administration of clesacostat (acetyl‐CoA carboxylase inhibitor, PF‐05221304) and ervogastat (diacylglycerol O‐acyltransferase inhibitor, PF‐06865571) in laboratory models improved non‐alcoholic fatty liver disease (NAFLD)/non‐alcoholic steatohepatitis (NASH) end points and mitigated clesacostat‐induced elevations in circulating triglycerides. Clesacostat is cleared via organic anion‐transporting polypeptide‐mediated hepatic uptake and cytochrome P450 family 3A (CYP3A); in vitro clesacostat is identified as a potential CYP3A time‐dependent inactivator. In vitro ervogastat is identified as a substrate and potential inducer of CYP3A. Prior to longer‐term efficacy trials in participants with NAFLD, safety and pharmacokinetics (PK) were evaluated in a phase I, non‐randomized, open‐label, fixed‐sequence trial in healthy participants. In Cohort 1, participants (n = 7) received clesacostat 15 mg twice daily (b.i.d.) alone (Days 1–7) and co‐administered with ervogastat 300 mg b.i.d. (Days 8–14). Mean systemic clesacostat exposures, when co‐administered with ervogastat, decreased by 12% and 19%, based on maximum plasma drug concentration and area under the plasma drug concentration–time curve during the dosing interval, respectively. In Cohort 2, participants (n = 9) received ervogastat 300 mg b.i.d. alone (Days 1–7) and co‐administered with clesacostat 15 mg b.i.d. (Days 8–14). There were no meaningful differences in systemic ervogastat exposures when administered alone or with clesacostat. Clesacostat 15 mg b.i.d. and ervogastat 300 mg b.i.d. co‐administration was overall safe and well tolerated in healthy participants. Cumulative safety and no clinically meaningful PK drug interactions observed in this study supported co‐administration of these two novel agents in additional studies exploring efficacy and safety in the management of NAFLD.
- 16 February 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (2) , e13687
Open AccessInvestigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants
Co‐administration of clesacostat (acetyl‐CoA carboxylase inhibitor, PF‐05221304) and ervogastat (diacylglycerol O‐acyltransferase inhibitor, PF‐06865571) in laboratory models improved non‐alcoholic fatty liver disease (NAFLD)/non‐alcoholic steatohepatitis (NASH) end points and mitigated clesacostat‐induced elevations in circulating triglycerides. Clesacostat is cleared via organic anion‐transporting polypeptide‐mediated hepatic uptake and cytochrome P450 family 3A (CYP3A); in vitro clesacostat is identified as a potential CYP3A time‐dependent inactivator. In vitro ervogastat is identified as a substrate and potential inducer of CYP3A. Prior to longer‐term efficacy trials in participants with NAFLD, safety and pharmacokinetics (PK) were evaluated in a phase I, non‐randomized, open‐label, fixed‐sequence trial in healthy participants. In Cohort 1, participants (n = 7) received clesacostat 15 mg twice daily (b.i.d.) alone (Days 1–7) and co‐administered with ervogastat 300 mg b.i.d. (Days 8–14). Mean systemic clesacostat exposures, when co‐administered with ervogastat, decreased by 12% and 19%, based on maximum plasma drug concentration and area under the plasma drug concentration–time curve during the dosing interval, respectively. In Cohort 2, participants (n = 9) received ervogastat 300 mg b.i.d. alone (Days 1–7) and co‐administered with clesacostat 15 mg b.i.d. (Days 8–14). There were no meaningful differences in systemic ervogastat exposures when administered alone or with clesacostat. Clesacostat 15 mg b.i.d. and ervogastat 300 mg b.i.d. co‐administration was overall safe and well tolerated in healthy participants. Cumulative safety and no clinically meaningful PK drug interactions observed in this study supported co‐administration of these two novel agents in additional studies exploring efficacy and safety in the management of NAFLD.
- 15 November 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 80 (2) , 362-377
Pharmacologic inhibition of lipogenesis for the treatment of NAFLD
- 15 November 2023
- Published by Elsevier in Journal of Hepatology
- Vol. 80 (2) , 362-377
Pharmacologic inhibition of lipogenesis for the treatment of NAFLD
- Open Access
- 17 January 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (4) , 992-1001
A phase 2a, randomized, double‐blind, placebo‐controlled, three‐arm, parallel‐group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF ‐06835919 in patients with non‐alcoholic fatty liver disease and type 2 diabetes
Aim: To assess the safety, tolerability and pharmacodynamics (PD) of the ketohexokinase inhibitor PF‐06835919 in participants with non‐alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D). Materials and methods: This double‐blind, placebo‐controlled, parallel‐group study enrolled adults with NAFLD (≥ 8% whole liver fat [WLF] using MRI proton density fat fraction [MRI‐PDFF]) and T2D on stable doses of metformin (≥ 500 mg/day). Participants received once‐daily placebo, PF‐06835919 150 or 300 mg for 16 weeks. Randomization (1:1:1) was via an interactive response technology system. Endpoints included percentage change from baseline (CFB) in WLF using MRI‐PDFF (primary endpoint) and CFB in HbA1c (co‐primary endpoint) at 16 weeks, PD, safety and tolerability. Results: Among 164 participants randomized and treated, 145 completed the treatment (placebo, n = 50; PF‐06835919 150 mg, n = 46; PF‐06835919 300 mg, n = 49). At week 16, least squares mean (90% confidence interval) percentage CFB in WLF was −5.26% (−12.86%, 2.99%), −17.05% (−24.01%, −9.46%) and −19.13% (−25.51%, −12.20%) in the placebo, PF‐06835919 150‐mg and 300‐mg groups, respectively (PF‐06835919 300‐mg group vs. placebo, P = .0288). Modest numerical reductions in HbA1c were observed in all groups that did not reach statistical significance. Treatment‐emergent adverse event incidence was similar across groups (40.7%, 45.5% and 32.7% in the placebo, PF‐06835919 150‐mg and 300‐mg groups, respectively), with no apparent dose‐related trend. Conclusions: PF‐06835919 administration over 16 weeks was generally safe and well tolerated and resulted in reductions in WLF in participants with NAFLD and T2D.
- 17 January 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (4) , 992-1001
Open AccessA phase 2a, randomized, double‐blind, placebo‐controlled, three‐arm, parallel‐group study to assess the efficacy, safety, tolerability and pharmacodynamics of PF ‐06835919 in patients with non‐alcoholic fatty liver disease and type 2 diabetes
Aim: To assess the safety, tolerability and pharmacodynamics (PD) of the ketohexokinase inhibitor PF‐06835919 in participants with non‐alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D). Materials and methods: This double‐blind, placebo‐controlled, parallel‐group study enrolled adults with NAFLD (≥ 8% whole liver fat [WLF] using MRI proton density fat fraction [MRI‐PDFF]) and T2D on stable doses of metformin (≥ 500 mg/day). Participants received once‐daily placebo, PF‐06835919 150 or 300 mg for 16 weeks. Randomization (1:1:1) was via an interactive response technology system. Endpoints included percentage change from baseline (CFB) in WLF using MRI‐PDFF (primary endpoint) and CFB in HbA1c (co‐primary endpoint) at 16 weeks, PD, safety and tolerability. Results: Among 164 participants randomized and treated, 145 completed the treatment (placebo, n = 50; PF‐06835919 150 mg, n = 46; PF‐06835919 300 mg, n = 49). At week 16, least squares mean (90% confidence interval) percentage CFB in WLF was −5.26% (−12.86%, 2.99%), −17.05% (−24.01%, −9.46%) and −19.13% (−25.51%, −12.20%) in the placebo, PF‐06835919 150‐mg and 300‐mg groups, respectively (PF‐06835919 300‐mg group vs. placebo, P = .0288). Modest numerical reductions in HbA1c were observed in all groups that did not reach statistical significance. Treatment‐emergent adverse event incidence was similar across groups (40.7%, 45.5% and 32.7% in the placebo, PF‐06835919 150‐mg and 300‐mg groups, respectively), with no apparent dose‐related trend. Conclusions: PF‐06835919 administration over 16 weeks was generally safe and well tolerated and resulted in reductions in WLF in participants with NAFLD and T2D.
- Top Cited Papers
- 11 October 2021
- Published by Springer Nature in Nature Medicine
- Vol. 27 (10) , 1836-1848
ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
Alterations in lipid metabolism might contribute to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). However, no pharmacological agents are currently approved in the United States or the European Union for the treatment of NAFLD. Two parallel phase 2a studies investigated the effects of liver-directed ACC1/2 inhibition in adults with NAFLD. The first study (NCT03248882) examined the effects of monotherapy with a novel ACC1/2 inhibitor, PF-05221304 (2, 10, 25 and 50 mg once daily (QD)), versus placebo at 16 weeks of treatment; the second study (NCT03776175) investigated the effects of PF-05221304 (15 mg twice daily (BID)) co-administered with a DGAT2 inhibitor, PF-06865571 (300 mg BID), versus placebo after 6 weeks of treatment. The primary endpoint in both studies was percent change from baseline in liver fat assessed by magnetic resonance imaging–proton density fat fraction. Dose-dependent reductions in liver fat reached 50–65% with PF-05221304 monotherapy doses ≥10 mg QD; least squares mean (LSM) 80% confidence interval (CI) was −7.2 (−13.9, 0.0), −17.1 (−22.7, −11.1), −49.9 (−53.3, −46.2), −55.9 (−59.0, −52.4) and −64.8 (−67.5, −62.0) with 16 weeks placebo and PF-05221304 2, 10, 25 and 50 mg QD, respectively. The overall incidence of adverse events (AEs) did not increase with increasing PF-05221304 dose, except for a dose-dependent elevation in serum triglycerides (a known consequence of hepatic acetyl-coenzyme A carboxylase (ACC) inhibition) in 23/305 (8%) patients, leading to withdrawal in 13/305 (4%), and a dose-dependent elevation in other serum lipids. Co-administration of PF-05221304 and PF-06865571 lowered liver fat compared to placebo (placebo-adjusted LSM (90% CI) −44.6% (−54.8, −32.2)). Placebo-adjusted LSM (90% CI) reduction in liver fat was −44.5% (−55.0, −31.7) and −35.4% (−47.4, −20.7) after 6 weeks with PF-05221304 or PF-06865571 alone. AEs were reported for 10/28 (36%) patients after co-administered PF-05221304 and PF-06865571, with no discontinuations due to AEs, and the ACC inhibitor-mediated effect on serum triglycerides was mitigated, suggesting that PF-05221304 and PF-06865571 co-administration has the potential to address some of the limitations of ACC inhibition alone.
- 11 October 2021
- Published by Springer Nature in Nature Medicine
- Vol. 27 (10) , 1836-1848
Top Cited PapersACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
Alterations in lipid metabolism might contribute to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). However, no pharmacological agents are currently approved in the United States or the European Union for the treatment of NAFLD. Two parallel phase 2a studies investigated the effects of liver-directed ACC1/2 inhibition in adults with NAFLD. The first study (NCT03248882) examined the effects of monotherapy with a novel ACC1/2 inhibitor, PF-05221304 (2, 10, 25 and 50 mg once daily (QD)), versus placebo at 16 weeks of treatment; the second study (NCT03776175) investigated the effects of PF-05221304 (15 mg twice daily (BID)) co-administered with a DGAT2 inhibitor, PF-06865571 (300 mg BID), versus placebo after 6 weeks of treatment. The primary endpoint in both studies was percent change from baseline in liver fat assessed by magnetic resonance imaging–proton density fat fraction. Dose-dependent reductions in liver fat reached 50–65% with PF-05221304 monotherapy doses ≥10 mg QD; least squares mean (LSM) 80% confidence interval (CI) was −7.2 (−13.9, 0.0), −17.1 (−22.7, −11.1), −49.9 (−53.3, −46.2), −55.9 (−59.0, −52.4) and −64.8 (−67.5, −62.0) with 16 weeks placebo and PF-05221304 2, 10, 25 and 50 mg QD, respectively. The overall incidence of adverse events (AEs) did not increase with increasing PF-05221304 dose, except for a dose-dependent elevation in serum triglycerides (a known consequence of hepatic acetyl-coenzyme A carboxylase (ACC) inhibition) in 23/305 (8%) patients, leading to withdrawal in 13/305 (4%), and a dose-dependent elevation in other serum lipids. Co-administration of PF-05221304 and PF-06865571 lowered liver fat compared to placebo (placebo-adjusted LSM (90% CI) −44.6% (−54.8, −32.2)). Placebo-adjusted LSM (90% CI) reduction in liver fat was −44.5% (−55.0, −31.7) and −35.4% (−47.4, −20.7) after 6 weeks with PF-05221304 or PF-06865571 alone. AEs were reported for 10/28 (36%) patients after co-administered PF-05221304 and PF-06865571, with no discontinuations due to AEs, and the ACC inhibitor-mediated effect on serum triglycerides was mitigated, suggesting that PF-05221304 and PF-06865571 co-administration has the potential to address some of the limitations of ACC inhibition alone.
- Open Access
- 1 June 2021
- Published by Elsevier in Molecular Metabolism
- Vol. 48, 101196
Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction
- 1 June 2021
- Published by Elsevier in Molecular Metabolism
- Vol. 48, 101196
Open AccessPharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction
- 14 September 2020
- Published by Springer Nature in Nature Metabolism
- Vol. 2 (10) , 1163-1178
De novo lipogenesis is essential for platelet production in humans
Acetyl-CoA carboxylase (ACC) catalyses the first step of de novo lipogenesis (DNL). Pharmacologic inhibition of ACC has been of interest for therapeutic intervention in a wide range of diseases. We demonstrate here that ACC and DNL are essential for platelet production in humans and monkeys, but in not rodents or dogs. During clinical evaluation of a systemically distributed ACC inhibitor, unexpected dose-dependent reductions in platelet count were observed. While platelet count reductions were not observed in rat and dog toxicology studies, subsequent studies in cynomolgus monkeys recapitulated these platelet count reductions with a similar concentration response to that in humans. These studies, along with ex vivo human megakaryocyte maturation studies, demonstrate that platelet lowering is a consequence of DNL inhibition likely to result in impaired megakaryocyte demarcation membrane formation. These observations demonstrate that while DNL is a minor quantitative contributor to global lipid balance in humans, DNL is essential to specific lipid pools of physiological importance.
- 14 September 2020
- Published by Springer Nature in Nature Metabolism
- Vol. 2 (10) , 1163-1178
De novo lipogenesis is essential for platelet production in humans
Acetyl-CoA carboxylase (ACC) catalyses the first step of de novo lipogenesis (DNL). Pharmacologic inhibition of ACC has been of interest for therapeutic intervention in a wide range of diseases. We demonstrate here that ACC and DNL are essential for platelet production in humans and monkeys, but in not rodents or dogs. During clinical evaluation of a systemically distributed ACC inhibitor, unexpected dose-dependent reductions in platelet count were observed. While platelet count reductions were not observed in rat and dog toxicology studies, subsequent studies in cynomolgus monkeys recapitulated these platelet count reductions with a similar concentration response to that in humans. These studies, along with ex vivo human megakaryocyte maturation studies, demonstrate that platelet lowering is a consequence of DNL inhibition likely to result in impaired megakaryocyte demarcation membrane formation. These observations demonstrate that while DNL is a minor quantitative contributor to global lipid balance in humans, DNL is essential to specific lipid pools of physiological importance.
- Open Access
- 1 January 2020
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 10 (4) , 829-851
Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems
- 1 January 2020
- Published by Elsevier in Cellular and Molecular Gastroenterology and Hepatology
- Vol. 10 (4) , 829-851
Open AccessAcetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems